Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Richard Hobbs; Oghenekome A. Gbinigie-Thompson; Milensu Shanyinde; Ly‐Mee Yu; Victoria Harris; Jienchi Dorward; Gail Hayward; Benjamin R. Saville; Nicholas Berry; Philip Evans; Nicholas Thomas; Mahendra Patel; Duncan Richards; Oliver van Hecke; Michelle A. Detry; Christina Saunders; Mark Fitzgerald; Jared Robinson; Charlotte Latimer-Bell; Julie Allen; Emma Ogburn; Jenna Grabey; Simon de Lusignan; Monique Andersson; Paul Little; Christopher Butler

doi:10.1016/j.jinf.2024.106248

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Evidence for the effect of favipiravir treatment of acute COVID-19 on recovery, hospital admissions and longer-term outcomes in community settings is limited.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hobbs et al. (2024) studied this question.

synapsesocial.com/papers/68e5a5f5b6db6435875402a8 https://doi.org/10.1016/j.jinf.2024.106248

View Full Paper

Ask AI

Bookmark

Share

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Ask about this paper

Abstract

Discussion

Cite This Study

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading